 Michael Bauer
Concepts (181)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 21 | 2024 | 3082 | 1.380 |
Why?
| | High-Throughput Nucleotide Sequencing | 5 | 2021 | 180 | 1.300 |
Why?
| | Mutation | 11 | 2021 | 1337 | 0.700 |
Why?
| | Gene Expression Profiling | 7 | 2024 | 1112 | 0.510 |
Why?
| | Software | 6 | 2021 | 280 | 0.480 |
Why?
| | Tumor Microenvironment | 4 | 2026 | 274 | 0.480 |
Why?
| | Plasma Cells | 4 | 2021 | 234 | 0.440 |
Why?
| | Neoplasms | 5 | 2026 | 1334 | 0.430 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2014 | 412 | 0.400 |
Why?
| | Expert Systems | 1 | 2012 | 5 | 0.380 |
Why?
| | Information Storage and Retrieval | 1 | 2012 | 63 | 0.370 |
Why?
| | Natural Language Processing | 1 | 2012 | 58 | 0.360 |
Why?
| | Clonal Evolution | 3 | 2016 | 59 | 0.340 |
Why?
| | Genomics | 5 | 2022 | 271 | 0.330 |
Why?
| | Sequence Analysis, RNA | 3 | 2024 | 96 | 0.330 |
Why?
| | Evolution, Molecular | 2 | 2021 | 97 | 0.330 |
Why?
| | Humans | 34 | 2026 | 53230 | 0.300 |
Why?
| | Immunotherapy | 2 | 2026 | 266 | 0.260 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 868 | 0.260 |
Why?
| | Re-Epithelialization | 1 | 2026 | 2 | 0.240 |
Why?
| | Isoantigens | 1 | 2026 | 15 | 0.240 |
Why?
| | Oncolytic Virotherapy | 1 | 2026 | 28 | 0.240 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2026 | 43 | 0.240 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2026 | 89 | 0.230 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 2 | 2024 | 123 | 0.230 |
Why?
| | Diabetic Foot | 1 | 2026 | 79 | 0.220 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2020 | 78 | 0.220 |
Why?
| | Genome, Human | 3 | 2021 | 121 | 0.220 |
Why?
| | Wound Healing | 1 | 2026 | 226 | 0.210 |
Why?
| | Paraffin Embedding | 1 | 2024 | 52 | 0.210 |
Why?
| | Formaldehyde | 1 | 2024 | 51 | 0.210 |
Why?
| | Pancreatic Neoplasms | 1 | 2026 | 219 | 0.200 |
Why?
| | Cell Differentiation | 1 | 2026 | 681 | 0.200 |
Why?
| | Transcriptome | 2 | 2024 | 367 | 0.190 |
Why?
| | Doxorubicin | 1 | 2024 | 247 | 0.190 |
Why?
| | Paraproteinemias | 1 | 2022 | 72 | 0.180 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 3 | 2021 | 69 | 0.180 |
Why?
| | Early Detection of Cancer | 1 | 2023 | 190 | 0.180 |
Why?
| | Gene Rearrangement | 2 | 2022 | 76 | 0.180 |
Why?
| | Telomere Homeostasis | 1 | 2021 | 11 | 0.170 |
Why?
| | Spliceosomes | 1 | 2021 | 10 | 0.170 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2021 | 48 | 0.170 |
Why?
| | DNA-Binding Proteins | 2 | 2021 | 423 | 0.170 |
Why?
| | Positron-Emission Tomography | 2 | 2022 | 298 | 0.170 |
Why?
| | RNA Splicing | 1 | 2021 | 43 | 0.170 |
Why?
| | Chromosome Aberrations | 2 | 2022 | 297 | 0.170 |
Why?
| | Alternative Splicing | 1 | 2021 | 61 | 0.170 |
Why?
| | Genes, Tumor Suppressor | 2 | 2021 | 73 | 0.160 |
Why?
| | Cell Cycle | 1 | 2021 | 237 | 0.160 |
Why?
| | Phosphoproteins | 1 | 2021 | 117 | 0.160 |
Why?
| | Prognosis | 6 | 2021 | 2118 | 0.160 |
Why?
| | Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.160 |
Why?
| | Bone Marrow | 2 | 2022 | 359 | 0.160 |
Why?
| | Ecosystem | 1 | 2021 | 99 | 0.160 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 112 | 0.150 |
Why?
| | Genes, myc | 1 | 2019 | 39 | 0.150 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 412 | 0.150 |
Why?
| | Algorithms | 4 | 2020 | 667 | 0.150 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 228 | 0.140 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 1180 | 0.140 |
Why?
| | Transcription Factors | 1 | 2021 | 571 | 0.140 |
Why?
| | Phosphotransferases | 1 | 2018 | 18 | 0.140 |
Why?
| | Mutagenesis | 1 | 2018 | 59 | 0.140 |
Why?
| | Oncogenes | 1 | 2018 | 61 | 0.140 |
Why?
| | Translocation, Genetic | 4 | 2021 | 266 | 0.140 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2018 | 133 | 0.140 |
Why?
| | Neoplasm, Residual | 1 | 2018 | 171 | 0.140 |
Why?
| | Sequence Analysis, DNA | 2 | 2017 | 216 | 0.130 |
Why?
| | Lung Neoplasms | 1 | 2023 | 645 | 0.130 |
Why?
| | Reproducibility of Results | 1 | 2021 | 1219 | 0.130 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2017 | 35 | 0.130 |
Why?
| | Flow Cytometry | 1 | 2018 | 400 | 0.130 |
Why?
| | Survival Rate | 4 | 2021 | 949 | 0.130 |
Why?
| | Chromosome Deletion | 1 | 2017 | 138 | 0.120 |
Why?
| | Disease Progression | 4 | 2021 | 880 | 0.120 |
Why?
| | Female | 11 | 2026 | 28782 | 0.110 |
Why?
| | Epigenomics | 1 | 2015 | 76 | 0.110 |
Why?
| | Cross-Linking Reagents | 1 | 2014 | 43 | 0.110 |
Why?
| | Protein Interaction Mapping | 1 | 2014 | 38 | 0.110 |
Why?
| | Male | 10 | 2026 | 27435 | 0.110 |
Why?
| | ras Proteins | 1 | 2014 | 64 | 0.110 |
Why?
| | Clone Cells | 3 | 2021 | 76 | 0.100 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 150 | 0.100 |
Why?
| | Aged | 7 | 2023 | 10429 | 0.100 |
Why?
| | Middle Aged | 7 | 2026 | 13419 | 0.100 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2018 | 610 | 0.100 |
Why?
| | Mass Spectrometry | 1 | 2014 | 294 | 0.100 |
Why?
| | RNA | 1 | 2013 | 173 | 0.090 |
Why?
| | Computational Biology | 2 | 2014 | 209 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2021 | 3494 | 0.090 |
Why?
| | Mice | 3 | 2026 | 5982 | 0.080 |
Why?
| | Cell Line, Tumor | 2 | 2026 | 1470 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2021 | 2318 | 0.080 |
Why?
| | Internet | 1 | 2012 | 265 | 0.080 |
Why?
| | Animals | 4 | 2026 | 13526 | 0.080 |
Why?
| | Gene Dosage | 2 | 2020 | 76 | 0.070 |
Why?
| | Databases, Factual | 1 | 2012 | 742 | 0.070 |
Why?
| | DNA, Neoplasm | 2 | 2020 | 146 | 0.070 |
Why?
| | DNA Mutational Analysis | 2 | 2020 | 179 | 0.070 |
Why?
| | DNA Copy Number Variations | 2 | 2021 | 117 | 0.070 |
Why?
| | Survival Analysis | 2 | 2021 | 659 | 0.070 |
Why?
| | Genomic Instability | 2 | 2018 | 88 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 647 | 0.060 |
Why?
| | HMGB1 Protein | 1 | 2026 | 22 | 0.060 |
Why?
| | Transplantation, Autologous | 2 | 2018 | 488 | 0.060 |
Why?
| | Keratinocytes | 1 | 2026 | 91 | 0.060 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2026 | 140 | 0.060 |
Why?
| | Tissue Fixation | 1 | 2024 | 35 | 0.050 |
Why?
| | Double-Blind Method | 1 | 2026 | 729 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 113 | 0.050 |
Why?
| | Humanities | 1 | 2023 | 1 | 0.050 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 15 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 145 | 0.050 |
Why?
| | Social Networking | 1 | 2023 | 19 | 0.050 |
Why?
| | Immunization | 1 | 2023 | 69 | 0.050 |
Why?
| | Canada | 1 | 2023 | 112 | 0.050 |
Why?
| | Adult | 4 | 2021 | 14534 | 0.050 |
Why?
| | Proteomics | 1 | 2026 | 336 | 0.050 |
Why?
| | Radiation Dosage | 1 | 2023 | 160 | 0.050 |
Why?
| | Signal Transduction | 2 | 2021 | 1748 | 0.050 |
Why?
| | Phylogeny | 1 | 2022 | 231 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2023 | 321 | 0.040 |
Why?
| | Myocardium | 1 | 2024 | 471 | 0.040 |
Why?
| | Mutation Rate | 1 | 2021 | 36 | 0.040 |
Why?
| | Cyclin D2 | 1 | 2020 | 21 | 0.040 |
Why?
| | Aneuploidy | 1 | 2020 | 17 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2026 | 1925 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-maf | 1 | 2020 | 19 | 0.040 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2020 | 30 | 0.040 |
Why?
| | Histone Code | 1 | 2020 | 32 | 0.040 |
Why?
| | Cyclin D1 | 1 | 2020 | 59 | 0.040 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2020 | 56 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2024 | 1544 | 0.040 |
Why?
| | Incidence | 1 | 2023 | 1085 | 0.040 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2020 | 76 | 0.040 |
Why?
| | Lymphoma, Follicular | 1 | 2020 | 27 | 0.040 |
Why?
| | Alleles | 1 | 2021 | 277 | 0.040 |
Why?
| | Protein Disulfide-Isomerases | 1 | 2019 | 12 | 0.040 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2019 | 13 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 640 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2021 | 598 | 0.040 |
Why?
| | Risk Factors | 2 | 2018 | 4017 | 0.040 |
Why?
| | Remission Induction | 1 | 2018 | 221 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2019 | 266 | 0.040 |
Why?
| | Histones | 1 | 2020 | 318 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 465 | 0.030 |
Why?
| | Loss of Heterozygosity | 1 | 2018 | 78 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 330 | 0.030 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 52 | 0.030 |
Why?
| | Rats | 1 | 2024 | 3162 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 62 | 0.030 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2017 | 8 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 87 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 27 | 0.030 |
Why?
| | Arkansas | 1 | 2023 | 2068 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 184 | 0.030 |
Why?
| | Fibroblast Growth Factors | 1 | 2017 | 52 | 0.030 |
Why?
| | STAT3 Transcription Factor | 1 | 2017 | 89 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2018 | 5595 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2017 | 152 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2018 | 563 | 0.030 |
Why?
| | Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| | Genes, p53 | 1 | 2016 | 51 | 0.030 |
Why?
| | NF-kappa B | 1 | 2018 | 327 | 0.030 |
Why?
| | DNA Methylation | 1 | 2020 | 592 | 0.030 |
Why?
| | Models, Genetic | 1 | 2016 | 169 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2016 | 148 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2016 | 191 | 0.030 |
Why?
| | Succinimides | 1 | 2014 | 5 | 0.030 |
Why?
| | Recurrence | 1 | 2016 | 694 | 0.030 |
Why?
| | Time Factors | 1 | 2021 | 2991 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2014 | 57 | 0.030 |
Why?
| | Software Design | 1 | 2013 | 13 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2016 | 774 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2013 | 28 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1043 | 0.030 |
Why?
| | Peptides | 1 | 2014 | 234 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2016 | 1031 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2020 | 1222 | 0.020 |
Why?
| | Cell Line | 1 | 2013 | 1016 | 0.020 |
Why?
| | Systems Biology | 1 | 2009 | 33 | 0.020 |
Why?
|
|
Bauer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|